Coagulazione, infiammazione e CVD

Titolo	Data creazione	Visite
Prevalence and Prognosis of Unrecognized Myocardial Infarction in Asymptomatic Patients With Diabetes: A Two- Center Study With Up to 5 Years of Follow-up	22 Luglio 2019	Visite: 47
Association of Galectin-3 with Diabetes Mellitus in the Dallas Heart Study	11 Luglio 2019	Visite: 34
Reversion from prediabetes to normoglycaemia and risk of cardiovascular disease and mortality: the Whitehall II cohort study	13 Giugno 2019	Visite: 69
Differences in Carotid Plaques Between Symptomatic Patients With and Without Diabetes Mellitus A CARE-II Study	21 Maggio 2019	Visite: 104
Cardiovascular Risk Factor Burden in People With Incident Type 2 Diabetes in the U.S. Receiving Antidiabetic and Cardioprotective Therapies	18 Aprile 2019	Visite: 111
Empagliflozin enhances human and murine cardiomyocyte glucose uptake by increased expression of GLUT1	26 Marzo 2019	Visite: 142
Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: The Atherosclerosis Risk in Communities study	18 Febbraio 2019	Visite: 115
Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure. Benefits of SGLT2 Inhibitors	25 Gennaio 2019	Visite: 177
One quarter of total myocardial infarctions are silent manifestation in patients with type 2 diabetes mellitus	28 Dicembre 2018	Visite: 160
Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction. The TOPCAT Trial	30 Novembre 2018	Visite: 133

Pagina 1 di 7

Ricerca

Cookie